We report a case of porphyria cutanea tarda associated with myelodysplastic syndrome in a patient after highdose chemotherapy and peripheral blood stem cell transplantation for recurrent non-Hodgkin's lymphoma. Bone Marrow Transplantation (2001) 27, 219-220.
Myelodysplastic syndrome occurs occasionally after highdose chemotherapy with autologous stem cell transplantation.
1,2 Porphyria cutanea tarda is an uncommon disorder characterized by vesicular lesions to sun-exposed areas of skin, often precipitated by alcohol, estrogens, or iron overload. We describe a rare complication of myelodysplastic syndrome associated with porphyria cutanea tarda in a patient after high-dose chemotherapy and autologous stem cell transplant for recurrent non-Hodgkin's lymphoma.
Case report
A 64-year-old female was initially diagnosed in 1995 with stage IIIA follicular mixed large and small cell non-Hodgkin's lymphoma. She was treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone and attained complete remission. In November 1996, she developed recurrent disease and was treated with two cycles of dexamethasone, high-dose Ara-C, and cisplatin. She then received high-dose cyclophosphamide 60 mg/kg daily for two doses and fractionated total body irradiation 1320 cGy over eight fractions in 4 days, followed by peripheral blood stem cell transplantation on 2 May 1997. Her post-transplant course was complicated by Candida esophagitis and herpes zoster along the distribution of the maxillary branch of the right trigeminal nerve. Myeloid engraftment (ANC Ͼ500/l for 3 consecutive days) was achieved by day 13. A year after transplant, her WBC count was 5200/l, hemoglobin 11.6 g/dl, and platelet count 113 000/l.
In December 1998, the patient developed pancytopenia. The WBC was 2200/l with 42% segmented neutrophils, 2% band neutrophils, 52% lymphocytes, 2% monocytes, and 2% eosinophils. Her platelet count was 36 000/l and hemoglobin 9.1 g/dl. A bone marrow aspiration and biopsy revealed a normocellular marrow and dysplastic hematopoiesis, consistent with myelodysplastic syndrome, refractory anemia. The diagnosis was supported by cytogenetic study of unstimulated bone marrow showing 44,XX,-7,der(15;17) (q10;q10),-20,+mar [3] /46,xx [17] .
The patient was treated conservatively and she required frequent packed red blood cell and platelet transfusions. Since May 1999, she has noticed the intermittent appearance of blisters on both hands. These lesions form a scab and disappear after a few weeks, with new blisters returning in an episodic manner. In August, she was readmitted to our institution with severe cellulitis of the left hand. The patient denied any recent exposure to chemicals or toxins. She denied tobacco or alcohol use. She was taking no medications, except for piperacillin/tazobactam and ciprofloxacin, which had been started the day before at the referring institution.
On physical examination, the second digit of her right hand had a single vesicular lesion. The dorsum of her left hand was edematous and her left thumb had a 1 cm vesicle with a violaceous base and surrounding erythema. No palpable lymphadenopathy was present. WBC count was 1000/l with 8% segmented neutrophils, 84% lymphocytes, and 8% monocytes, hemoglobin of 8.1 g/dl, and platelet count of 9000/l. Serum creatinine was 0.6 mg/dl (normal, 0.5-1.5), AST 27 U/l (normal, 5-35), total bilirubin of 1.4 mg/dl (normal, 0.1-1.2) and alkaline phosphatase of 145 U/l (normal, 30-100). Iron studies revealed an iron level of 133 g/dl (normal, 40-160 g/dl), iron binding capacity of 154 g/dl (normal, 230-500 g/dl), 86% saturation (normal, 15-50%), and ferritin of 3516 g/l (normal, 20-200 g/l). Computed tomography of the chest, abdomen and pelvis revealed no evidence of recurrent lymphoma. Wound culture revealed mixed growth of Klebsiella ozaenae, Klebsiella pneumoniae and Enterobacter cloacae. Skin biopsy revealed a subepidermal vesicle with scanty cellular infiltrate. The possibility of porphyria cutanea tarda was raised and was subsequently confirmed by 24 h urine for porphyrins (Table 1) . The patient was treated conservatively. Porphyrinogenic drugs were avoided. Phlebotomy was not appropriate, given her low hemoglobin level. The wound infection improved with antibiotics and the vesicular lesions remained stable.
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Discussion
Sporadic porphyria cutanea tarda is generally precipitated by exposure to extrinsic agents such as alcohol, estrogens, or iron overload. In our patient, frequent blood transfusions led to iron overload as documented by a high ferritin level. This led to the subsequent development of the classic signs and symptoms of porphyria cutanea tarda. The association between excess iron and porphyrias has been suggested. Using electron microscopy, uroporphyrin crystals have been observed in the same hepatocyte as ferritin in patients with porphyria cutanea tarda, suggesting a direct role in the pathogenesis of this disease. 3 Iron overload is a known precipitating factor for unmasking the symptoms of porphyria cutanea tarda. However, most patients with transfusional iron overload or hemochromatosis do not develop porphyria.
Malignant lymphoma has been associated with porphyria cutanea tarda. 4, 5 However, our patient has no evidence of lymphoma based on follow-up CT scans of the chest, abdomen, and pelvis. Whether acquired PCT is related to highdose chemotherapy and autologous peripheral blood stem cell transplantation is intriguing, but speculative. It is unclear whether the underlying acquired chromosomal abnormalities in our patient predisposed her to porphyria cutanea tarda. A homozygous mutation in the gene locus 7q22, which encodes transferrin receptor-2, was recently described in patients with hemochromatosis. 6 While our patient had a single deletion of chromosome 7, implicating this deletion as a contributing factor to porphyria cutanea tarda would also be speculative.
The diagnosis of porphyria cutanea tarda requires a high index of suspicion. We believe this is the first case report of porphyria cutanea tarda associated with myelodysplastic syndrome after autologous peripheral blood stem cell transplantation.
